BPC-157Prescription BPC-157
BPC-157 Injection: A Prescription Peptide Vial
Still feeling the same tendon?
Injection vialYour BPC-157 vial
15 mg in 5 mL at 3 mg/mL.
BPC-157 comes as a prescription injection vial with 15 mg in 5 mL at 3 mg/mL, a 30-day supply. Your clinician sets the directions.
- Format
- Injection vial
- Strength
- 3 mg/mL, 15 mg in 5 mL
- Supply
- 30 days
- Directions
- Set by your clinician and printed on the prescription label
Compounded medications are prepared by a licensed 503A compounding pharmacy for an individual patient's prescription. Compounded drugs are not FDA-approved and have not been evaluated by the FDA for safety or effectiveness.
Start your online visitBPC-157, prescribed online.
Rebody offers BPC-157 as a prescription injection vial with 15 mg in 5 mL at 3 mg/mL, a 30-day supply. Your clinician sets the directions.
On October 28, 2026, HHS announced an interim policy that lets licensed 503A compounding pharmacies prepare six peptides under set conditions. This is not FDA approval. BPC-157 is one of the six. Rebody offers it as a single-ingredient injection vial, prescribed only after a licensed clinician reviews your online visit.
No. Compounded medications are not FDA-approved. A BPC-157 prescription is prepared for an individual patient by a licensed U.S. compounding pharmacy.
No. The prescription specifies the strength, amount, timing, quantity, and supply.
BPC-157 is prescription-only in the US. Start an online visit, and a licensed U.S. provider reviews it. A licensed 503A pharmacy prepares BPC-157 only if it is prescribed.
Check for a prescription written after a provider review, a named U.S.-licensed 503A pharmacy, a label with your name, strength, lot, and expiry date, and a clinician or pharmacist you can reach. A product labeled "not for human use" is not a prescription medication.
No. A prescription is required. A licensed U.S. provider reviews your visit first, and a licensed 503A pharmacy prepares it only if it is prescribed.
The evidence
What the BPC-157 studies measured.
Rats, Achilles tendon | After the tendon was cut, function was checked daily; tissue and biomechanics were examined at five points over 14 days. Staresinic M, et al. J Orthop Res. 2003. |
Rats, knee ligament | After the medial collateral ligament was cut, rats were followed for up to 90 days on functional, biomechanical, microscopic, and visible repair measures. |
Mice, rats, rabbits, and dogs, safety | The authors reported no serious toxicity across single-dose, repeated-dose, genetic, and embryo-development tests. FDA's 2026 review of the same data flagged clotting-time changes and liver-related lab values in rats and dogs given daily injections for 28 days. Xu C, et al. Regul Toxicol Pharmacol. 2020.
|
People, knee pain | A retrospective case series of 16 adults who received BPC-157 injected into the knee, some with thymosin beta-4. It had no control group. Lee E, Padgett B. Altern Ther Health Med. 2021.
|
Questions, answered
FAQs about BPC-157 injections.
How quickly do BPC-157 injections work?
No human study has measured how quickly BPC-157 works. In rats, the tendon study ran 14 days, and the ligament study ran up to 90 days. Individual responses vary, and your provider reviews your progress with you.
What are the reported side effects of BPC-157?
Human reports are limited. FDA adverse event reports describe injection-site redness and swelling, shortness of breath, and skin and gum darkening with a product that also contained another peptide, and none could be firmly tied to BPC-157. Small human pilot studies reported no serious adverse events, but they were short and limited in their safety monitoring.
Is BPC-157 hard on the liver or kidneys?
Human data does not answer this. In 28-day injection studies in rats and dogs, FDA flagged higher liver-related lab values and lower creatinine, a kidney marker, in dogs. The study authors described the findings as not serious. Your provider reviews your health history before prescribing.
How do you know a BPC-157 injection is legitimate?
Check for a prescription written after a provider review, a named U.S.-licensed 503A pharmacy, a label with your name, strength, lot, and expiry date, and a clinician or pharmacist you can reach. A product labeled "not for human use" is not a prescription medication.
Is BPC-157 FDA-approved?
No. Under section 503A, a licensed pharmacy compounds a medication for one patient against that patient's prescription. Compounded medications are not FDA-approved, which means FDA does not review them for safety, effectiveness, or quality before they reach patients.
Can I get a BPC-157 injection without a prescription?
No. A prescription is required. A licensed U.S. provider reviews your visit first, and a licensed 503A pharmacy prepares it only if it is prescribed.
Important safety information
Before you start a BPC-157 injection.
Side effects of BPC-157 injections reported so far include injection-site redness and swelling. In animal testing, the FDA's review flagged clotting-time and liver-related lab changes in rats and dogs. Human data is limited to small, short studies, so long-term effects in people are unknown.
It may not be right for you if you have active cancer, are pregnant or breastfeeding, or have a clotting disorder. Tell your provider about every medicine, supplement, allergy, and health condition before you start. BPC-157 is on the World Anti-Doping Agency Prohibited List.
Seek urgent medical help for signs of a serious allergic reaction. A licensed provider decides whether treatment is appropriate for you, and individual results vary.
Compounded medications are not FDA-approved.
Still deciding?
Talk with the Rebody care team before you start. Call 650-535-8019